Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Al Blunt
Galunisertib Plus Gemcitabine vs. Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
British Journal of Cancer
Cancer Research
Oncology
Related publications
Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer
Cancer Management and Research
Oncology
Neoadjuvant Treatment With Gemcitabine Plus Nab-Paclitaxel Versus Surgery First for Pancreatic Adenocarcinoma
HPB
Hepatology
Gastroenterology
A Phase I Study of Imexon Plus Gemcitabine as First-Line Therapy for Advanced Pancreatic Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Intra-Arterial and Tumor-Targeted Infusion of Gemcitabine in Patients With Unresectable Pancreatic Cancer
HPB
Hepatology
Gastroenterology
Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study
British Journal of Cancer
Cancer Research
Oncology
Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine
Oncology Letters
Cancer Research
Oncology
